A case of recurrent gastrointestinal stromal tumor of the stomach with complete response to imatinib mesilate

Japanese Journal of Cancer and Chemotherapy

Volumn 36, Issue 6, 2009, Pages 975-978

  Aoyama, Toru ^a   Saeki, Hiroyuki ^a   Samejima, Jouji ^a   Fujii, Keita ^a   Ishikawa, Yoshihiro ^a   Kawamoto, Masakazu ^a   Fujisawa, Jun ^a   Matsukawa, Hiroshi ^a   Rino, Yasushi ^b   Masuda, Munetaka ^b  

^a Yokohama Minami Kyosai Hospital   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Complete response (CR); GIST; Lmatinib mesilate

Indexed keywords

CD34 ANTIBODY; IMATINIB; MONOCLONAL ANTIBODY HMB 45; PROTEIN S 100;

ADULT; ANEMIA; ARTICLE; BODY WEIGHT; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CASE REPORT; DRUG DOSE REDUCTION; EDEMA; EMERGENCY SURGERY; ENDOSCOPY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HEMOSTASIS; HUMAN; IMMUNOHISTOLOGY; LAPAROTOMY; MELANOMA; PANCREAS RESECTION; SIDE EFFECT; SKIN TUMOR; SPLENECTOMY; STOMACH MUCOSA; STOMACH TUMOR; STOMACH WALL; TOTAL STOMACH RESECTION; TREATMENT RESPONSE; TUMOR RECURRENCE; TUMOR VOLUME;

EID: 79959830368     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344: 1052-1056, 2001.
2. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480, 2002.
3. Nishida T, Shirao K, Yamano K, et al: Preliminary results of the phase II clinical trial of imatinib mesylate for advanced gastorointestinal stromal tumors in Japan. GANN Monograph on Cancer Research, Tokyo, 2004, pp 151-157.
4. Blay JY, Berthaud P, Perol D, et al: Continuous vs intermittent imatinib treatment in advanced GIST after one year: a prospective randomized phase III trial of the French Sarcoma Group. Proc ASCO 23: 815, 2004.